Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Triple-drug versus two-drug mass drug administration for lymphatic filariasis, scabies, impetigo, and soil-transmitted helminths in Fiji
ACTRN12617000738325Phase 4Completed
- Sponsor
- Murdoch Children's Research Institute
- Start
- Jul 2017
- Modality
- Small Molecules, Allosteric Modulators → Classical Binding Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of ivermectin, diethylcarbamazine, albendazole and permethrin in filariasis, scabies and Soil-Transmitted Helminthiases (STH) (3 arms), sponsored by Murdoch Children's Research Institute. Primary endpoint: Frequency, type, and severity of adverse events after IDA versus DA. Started Jul 2017; status: completed.
02
Drugs
ivermectindiethylcarbamazinealbendazolepermethrin
03
Conditions
filariasisscabiesSoil-Transmitted Helminthiases (STH)
Beyond the preview
Go deeper on ACTRN12617000738325.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12617000738325.